Efficacy of Vonoprazan for Helicobacter pylori Eradication
Helicobacter pylori can infect the gastric mucosa and cause chronic inflammation, resulting in various diseases, including gastric cancer. Eradication of H. pylori in all infected subjects is recommended; however, the number of H. pylori strains with antibiotic resistance has increased, and the erad...
Saved in:
| Published in | Internal Medicine Vol. 59; no. 2; pp. 153 - 161 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
The Japanese Society of Internal Medicine
15.01.2020
Japan Science and Technology Agency |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0918-2918 1349-7235 1349-7235 |
| DOI | 10.2169/internalmedicine.2521-18 |
Cover
Loading…
| Abstract | Helicobacter pylori can infect the gastric mucosa and cause chronic inflammation, resulting in various diseases, including gastric cancer. Eradication of H. pylori in all infected subjects is recommended; however, the number of H. pylori strains with antibiotic resistance has increased, and the eradication rate has decreased. Vonoprazan, a potassium-competitive acid blocker, produces a stronger acid-inhibitory effect than proton pump inhibitors (PPIs). The H. pylori eradication rate with vonoprazan was found to be higher than that with PPIs. The H. pylori eradication rate with vonoprazan-based triple therapy (vonoprazan, amoxicillin, and clarithromycin) was approximately 90% and had an incidence of adverse events similar to that of PPIs. We review the current situation of H. pylori eradication in Japan, the first country in which vonoprazan was made available. |
|---|---|
| AbstractList | Helicobacter pylori can infect the gastric mucosa and cause chronic inflammation, resulting in various diseases, including gastric cancer. Eradication of H. pylori in all infected subjects is recommended; however, the number of H. pylori strains with antibiotic resistance has increased, and the eradication rate has decreased. Vonoprazan, a potassium-competitive acid blocker, produces a stronger acid-inhibitory effect than proton pump inhibitors (PPIs). The H. pylori eradication rate with vonoprazan was found to be higher than that with PPIs. The H. pylori eradication rate with vonoprazan-based triple therapy (vonoprazan, amoxicillin, and clarithromycin) was approximately 90% and had an incidence of adverse events similar to that of PPIs. We review the current situation of H. pylori eradication in Japan, the first country in which vonoprazan was made available. Helicobacter pylori can infect the gastric mucosa and cause chronic inflammation, resulting in various diseases, including gastric cancer. Eradication of H. pylori in all infected subjects is recommended; however, the number of H. pylori strains with antibiotic resistance has increased, and the eradication rate has decreased. Vonoprazan, a potassium-competitive acid blocker, produces a stronger acid-inhibitory effect than proton pump inhibitors (PPIs). The H. pylori eradication rate with vonoprazan was found to be higher than that with PPIs. The H. pylori eradication rate with vonoprazan-based triple therapy (vonoprazan, amoxicillin, and clarithromycin) was approximately 90% and had an incidence of adverse events similar to that of PPIs. We review the current situation of H. pylori eradication in Japan, the first country in which vonoprazan was made available.Helicobacter pylori can infect the gastric mucosa and cause chronic inflammation, resulting in various diseases, including gastric cancer. Eradication of H. pylori in all infected subjects is recommended; however, the number of H. pylori strains with antibiotic resistance has increased, and the eradication rate has decreased. Vonoprazan, a potassium-competitive acid blocker, produces a stronger acid-inhibitory effect than proton pump inhibitors (PPIs). The H. pylori eradication rate with vonoprazan was found to be higher than that with PPIs. The H. pylori eradication rate with vonoprazan-based triple therapy (vonoprazan, amoxicillin, and clarithromycin) was approximately 90% and had an incidence of adverse events similar to that of PPIs. We review the current situation of H. pylori eradication in Japan, the first country in which vonoprazan was made available. Helicobacter pylori can infect the gastric mucosa and cause chronic inflammation, resulting in various diseases, including gastric cancer. Eradication of H. pylori in all infected subjects is recommended; however, the number of H. pylori strains with antibiotic resistance has increased, and the eradication rate has decreased. Vonoprazan, a potassium-competitive acid blocker, produces a stronger acid-inhibitory effect than proton pump inhibitors (PPIs). The H. pylori eradication rate with vonoprazan was found to be higher than that with PPIs. The H. pylori eradication rate with vonoprazan-based triple therapy (vonoprazan, amoxicillin, and clarithromycin) was approximately 90% and had an incidence of adverse events similar to that of PPIs. We review the current situation of H. pylori eradication in Japan, the first country in which vonoprazan was made available. |
| Author | Nishikawa, Jun Sakaida, Isao Kiyotoki, Shu |
| Author_xml | – sequence: 1 fullname: Sakaida, Isao organization: Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Japan – sequence: 1 fullname: Nishikawa, Jun organization: Faculty of Laboratory Science, Yamaguchi University Graduate School of Medicine, Japan – sequence: 1 fullname: Kiyotoki, Shu organization: Department of Gastroenterology, Shuto General Hospital, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31243237$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkU1vEzEQhi1URNPCX0ArceGyxR-7XpsDEqoCRargAlytWWfcOnLsYG-Qwq_HacoC5YIPY0t-5p2Zd87ISUwRCWkYveBM6lc-TpgjhA2uvPURL3jPWcvUI7JgotPtwEV_QhZUM9XyGk7JWSlrSoUaNH9CTgXjneBiWJDXS-e8Bbtvkmu-ppi2GX5AbFzKzRUGb9MIthZrtvuQsm-WGWpJmHyKT8ljB6Hgs_v7nHx5t_x8edVef3r_4fLtdWullFMrhEWlKMMRELDvmVS2nt7yoXaj0MFIVVefWnHp-GqFVPXSDVJrO0q9EufkzVF3uxvrwBbjlCGYbfYbyHuTwJu_f6K_NTfpuxkoVbRjVeDlvUBO33ZYJrPxxWIIEDHtiuG8U2Lome4q-uIBuk67g9OVqsaqgWnOK_X8z47mVn7ZWgF1BGxOpWR0M8KoOWzQPNygOWzQMPV72jnV-unO7zqbD_8j8PEosC4T3OBcGfLkbcB_E3tt-F04CsygvYVsMIqfKj3HQw |
| CitedBy_id | crossref_primary_10_1080_17474124_2021_1826306 crossref_primary_10_2169_internalmedicine_0789_22 crossref_primary_10_1007_s42452_024_05923_0 crossref_primary_10_1177_17562848231168714 crossref_primary_10_1080_1120009X_2024_2405353 crossref_primary_10_1007_s40266_023_01090_w crossref_primary_10_1007_s10620_023_07886_5 crossref_primary_10_1016_j_arcmed_2022_08_010 crossref_primary_10_3390_jcm11175086 crossref_primary_10_1016_j_ejps_2024_106840 crossref_primary_10_1016_j_bioorg_2025_108218 crossref_primary_10_1111_jgh_16761 crossref_primary_10_1002_jpn3_12242 crossref_primary_10_1007_s00535_020_01723_6 crossref_primary_10_3390_pharmaceutics14071340 crossref_primary_10_1111_hel_12918 crossref_primary_10_3389_fmed_2023_1267180 crossref_primary_10_1038_s41598_024_59621_3 crossref_primary_10_1111_hel_12830 crossref_primary_10_1556_030_2022_01682 crossref_primary_10_1111_hel_13129 crossref_primary_10_7704_kjhugr_2024_0012 crossref_primary_10_1097_MCG_0000000000002001 crossref_primary_10_11569_wcjd_v32_i9_665 crossref_primary_10_1111_jcpt_13637 crossref_primary_10_3390_antibiotics11101452 crossref_primary_10_1007_s00535_022_01942_z crossref_primary_10_1111_jgh_16679 crossref_primary_10_1007_s11030_022_10387_8 crossref_primary_10_3390_ijms24032281 crossref_primary_10_1002_med_21976 crossref_primary_10_1186_s13099_023_00551_2 crossref_primary_10_1248_bpb_b24_00011 crossref_primary_10_7759_cureus_64777 crossref_primary_10_1007_s12602_024_10396_z crossref_primary_10_1097_MOG_0000000000000981 crossref_primary_10_1177_20587384211030397 crossref_primary_10_3390_jcm11237040 crossref_primary_10_3390_ph13100276 crossref_primary_10_2169_internalmedicine_1282_22 crossref_primary_10_1159_000541173 crossref_primary_10_12677_ACM_2022_12121722 crossref_primary_10_1038_s41598_021_95124_1 crossref_primary_10_1186_s43556_023_00138_y crossref_primary_10_1093_jac_dkae467 crossref_primary_10_1136_gutjnl_2021_325630 crossref_primary_10_3748_wjg_v31_i10_102289 crossref_primary_10_1016_j_dld_2022_06_019 crossref_primary_10_1177_10600280221149708 crossref_primary_10_3390_antibiotics12020191 crossref_primary_10_1016_j_ejmech_2024_116759 crossref_primary_10_3390_tropicalmed8030172 crossref_primary_10_1097_MCG_0000000000002100 crossref_primary_10_1186_s43162_024_00376_8 crossref_primary_10_31146_1682_8658_ecg_212_4_86_92 crossref_primary_10_1093_gastro_goae036 crossref_primary_10_3390_antibiotics12020346 crossref_primary_10_1038_s41575_021_00449_x crossref_primary_10_1002_jcla_24885 crossref_primary_10_1186_s12879_024_09885_x crossref_primary_10_12998_wjcc_v10_i19_6349 crossref_primary_10_46563_1560_9561_2023_26_1_67_74 crossref_primary_10_1016_j_ejmech_2024_116446 crossref_primary_10_1007_s00228_022_03430_y crossref_primary_10_12677_acm_2024_14102721 crossref_primary_10_14309_ajg_0000000000002592 crossref_primary_10_3389_fphar_2023_1143969 crossref_primary_10_3904_kjim_2022_345 |
| Cites_doi | 10.1046/j.1523-5378.2000.00013.x 10.1592/phco.23.4.460.32128 10.1038/ajg.2016.182 10.1111/j.1523-5378.2007.00563.x 10.1124/jpet.110.170274 10.1002/14651858.CD003840.pub5 10.1136/gut.2009.192757 10.15403/jgld.2014.1121.253.7hp 10.1016/S0140-6736(08)61159-9 10.1111/hel.12124 10.5694/j.1326-5377.1985.tb113443.x 10.1111/hel.12438 10.1046/j.1523-5378.2001.00037.x 10.1111/j.1523-5378.2009.00738.x 10.1136/gutjnl-2016-312288 10.1007/s11894-011-0226-4 10.1038/ctg.2015.18 10.1111/hel.12146 10.1111/hel.12495 10.1111/j.1523-5378.2007.00508.x 10.1080/00498254.2016.1203505 10.1111/j.1523-5378.1996.tb00008.x 10.3892/br.2018.1111 10.1186/s12941-018-0281-x 10.3748/wjg.v20.i29.9912 10.1111/j.1523-5378.2009.00664.x 10.1002/ijc.27965 10.1046/j.1365-2036.2001.00929.x 10.1111/j.1440-1746.2007.04845.x 10.1111/j.1365-2710.2009.01092.x 10.3164/jcbn.16-86 10.1136/gut.43.2008.S56 10.1016/j.kjms.2016.04.009 10.1111/jgh.14456 10.1136/gutjnl-2015-311304 10.1007/s005350050150 10.1002/14651858.CD008337.pub2 10.1111/hel.12456 10.1080/00365521.2016.1250157 10.1159/000454762 10.4292/wjgpt.v7.i4.550 10.1111/apt.13414 10.1136/gutjnl-2011-300495 10.1067/mcp.2001.113959 10.2133/dmpk.20.153 |
| ContentType | Journal Article |
| Copyright | 2020 by The Japanese Society of Internal Medicine Copyright Japan Science and Technology Agency 2020 Copyright © 2020 by The Japanese Society of Internal Medicine |
| Copyright_xml | – notice: 2020 by The Japanese Society of Internal Medicine – notice: Copyright Japan Science and Technology Agency 2020 – notice: Copyright © 2020 by The Japanese Society of Internal Medicine |
| DBID | AAYXX CITATION NPM 7T5 7TK 7U9 H94 K9. 7X8 5PM |
| DOI | 10.2169/internalmedicine.2521-18 |
| DatabaseName | CrossRef PubMed Immunology Abstracts Neurosciences Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1349-7235 |
| EndPage | 161 |
| ExternalDocumentID | PMC7008041 31243237 10_2169_internalmedicine_2521_18 article_internalmedicine_59_2_59_2521_18_article_char_en |
| Genre | Journal Article |
| GroupedDBID | --- 29J 2WC 5GY ACPRK ADBBV AENEX AFRAH ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CS3 DIK DU5 EBS EJD F5P HYE JSF JSH M48 OK1 OVT P2P PGMZT RJT RNS RPM RZJ TR2 XSB AAYXX CITATION NPM 7T5 7TK 7U9 H94 K9. 7X8 5PM |
| ID | FETCH-LOGICAL-c666t-33ce8801ebaeae55168cccc5c278798efab0848799826f2dde0856f7699cb69d3 |
| IEDL.DBID | M48 |
| ISSN | 0918-2918 1349-7235 |
| IngestDate | Thu Aug 21 13:59:44 EDT 2025 Fri Jul 11 02:47:53 EDT 2025 Mon Jun 30 07:52:45 EDT 2025 Thu Apr 03 07:06:23 EDT 2025 Thu Apr 24 22:51:10 EDT 2025 Tue Jul 01 01:40:11 EDT 2025 Wed Sep 03 06:25:58 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | proton pump inhibitor (PPI) Helicobacter pylori vonoprazan potassium-competitive acid blocker (P-CAB) eradication |
| Language | English |
| License | The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c666t-33ce8801ebaeae55168cccc5c278798efab0848799826f2dde0856f7699cb69d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 Correspondence to Dr. Shu Kiyotoki, shu2026eb@hi.enjoy.ne.jp |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.2169/internalmedicine.2521-18 |
| PMID | 31243237 |
| PQID | 2349871922 |
| PQPubID | 2048449 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7008041 proquest_miscellaneous_2248375194 proquest_journals_2349871922 pubmed_primary_31243237 crossref_primary_10_2169_internalmedicine_2521_18 crossref_citationtrail_10_2169_internalmedicine_2521_18 jstage_primary_article_internalmedicine_59_2_59_2521_18_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-01-15 |
| PublicationDateYYYYMMDD | 2020-01-15 |
| PublicationDate_xml | – month: 01 year: 2020 text: 2020-01-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan – name: Tokyo |
| PublicationTitle | Internal Medicine |
| PublicationTitleAlternate | Intern. Med. |
| PublicationYear | 2020 |
| Publisher | The Japanese Society of Internal Medicine Japan Science and Technology Agency |
| Publisher_xml | – name: The Japanese Society of Internal Medicine – name: Japan Science and Technology Agency |
| References | 6. Ford AC, Gurusamy KS, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev 4: CD003840, 2016. 28. Matsumoto H, Shiotani A, Katsumata R, et al. Helicobacter pylori eradication with proton pump inhibitors or potassium-competitive acid blockers: the effect of clarithromycin resistance. Dig Dis Sci 61: 3215-3220, 2016. 39. Lee SY. Current progress toward eradicating Helicobacter pylori in East Asian countries: differences in the 2013 revised guidelines between China, Japan, and South Korea. World J Gastroenterol 20: 1493-1502, 2014. 11. Satake M, Nishikawa J, Fukagawa Y, et al. The long-term efficacy of Helicobacter pylori eradication therapy in patients with idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol 22: 2233-2237, 2007. 48. Sachs G, Meyer-Rosberg K, Scott DR, Melchers K. Acid, protons and Helicobacter pylori. Yale J Biol Med 69: 301-316, 1996. 15. Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 335: 231-238, 2010. 22. Sue S, Kuwashima H, Iwata Y, et al. The superiority of vonoprazan-based first-line triple therapy with clarithromycin: a prospective multi-center cohort study on Helicobacter pylori eradication. Intern Med 56: 1277-1285, 2017. 46. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 39: 5-12, 1997. 43. Sue S, Ogushi M, Arima I, et al. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: a multicenter, prospective, randomized trial. Helicobacter 23: e12456, 2018. 13. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 66: 6-30, 2017. 3. Morris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 82: 192-199, 1987. 24. Ozaki H, Harada S, Takeuchi T, et al. Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: a large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy. Digestion 97: 212-218, 2018. 26. Sue S, Shibata W, Sasaki T, et al. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. J Gastroenterol Hepatol 2018 (Epub ahead of print). 10. Yoon SB, Park JM, Lim CH, Cho YK, Choi MG. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter 19: 243-248, 2014. 34. Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day ppi-based low-dose clarithromycin triple therapy. Am J Gastroenterol 111: 949-956, 2016. 9. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372: 392-397, 2008. 36. Yamada S, Kawakami T, Nakatsugawa Y, et al. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther 7: 550-555, 2016. 59. Okada M, Oki K, Shirotani T, et al. A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol 33: 640-645, 1998. 1. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1: 1273-1275, 1983. 21. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 65: 1439-1446, 2016. 19. Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol 6: e94, 2015. 20. Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 41: 636-648, 2015. 49. Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut 43 (Suppl 1): S56-S60, 1998. 52. Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 12: 317-323, 2007. 55. Okamura T, Suga T, Nagaya T, et al. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. Helicobacter 19: 214-220, 2014. 60. Koizumi W, Tanabe S, Nakatani K, et al. Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study). J Clin Pharm Ther 35: 303-307, 2010. 5. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 12 (Suppl 2): 32-38, 2007. 14. Smith SM, O'Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol 20: 9912-9921, 2014. 18. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 23: 460-471, 2003. 2. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust 142: 436-439, 1985. 45. Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K, Hasegawa S. Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized, crossover study. Adv Ther 33: 1519-1535, 2016. 29. Nishizawa T, Suzuki H, Fujimoto A, et al. Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection. J Clin Biochem Nutr 60: 208-210, 2017. 57. Yanai A, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: a randomized study in Japan. World J Gastrointest Pharmacol Ther 3: 1-6, 2012. 40. Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther 46: 106-114, 2017. 47. Takeda Pharmaceutical Company Limited. Takecab® 10mg/20mg Interview Form [Internet]. [cited 2018 Nov 1]. Available from: https://www.takedamed.com/mcm/medicine/download.jsp?id=162&type=INTERVIEW_FORM (in Japanese) 32. Shichijo S, Hirata Y, Niikura R, et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: a multicenter retrospective study in clinical practice. J Dig Dis 17: 670-675, 2016. 37. Tanabe H, Yoshino K, Ando K, et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Clin Microbiol Antimicrob 17: 29, 2018. 44. Asaka M, Sugiyama T, Kato M, et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6: 254-261, 2001. 31. Sakurai K, Suda H, Ido Y, et al. Comparative study: vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol 23: 668-675, 2017. 16. Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Aliment Pharmacol Ther 42: 1315-1326, 2015. 61. Nagahara A, Miwa H, Ogawa K, et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 5: 88-93, 2000. 51. Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69: 158-168, 2001. 64. Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer 132: 1272-1276, 2013. 23. Maruyama M, Tanaka N, Kubota D, et al. Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial. Can J Gastroenterol Hepatol 2017: 4385161, 2017. 58. Okada M, Nishimura H, Kawashima M, et al. A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome. Aliment Pharmacol Ther 13: 769-774, 1999. 54. Sugimoto M, Ban H, Hira D, et al. Letter: CYP3A4/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan. Aliment Pharmacol Ther 45: 1009-1010, 2017. 62. Nagahara A, Miwa H, Yamada T, Kurosawa A, Ohkura R, Sato N. Five-day proton pump inhibitor-based quadruple therapy regimen is more 44 45 46 47 49 50 51 52 53 10 54 11 55 56 13 57 14 58 15 59 16 17 18 19 D Scott (48) 1998; 43 2 3 4 5 6 8 60 61 62 63 20 64 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 M Asaka (12) 2010; 15 JR Warren (1) 1983; 1 K Fukase (9) 2008; 372 S Nakamura (7) 2012; 61 40 41 42 43 |
| References_xml | – reference: 53. Yamasaki H, Kawaguchi N, Nonaka M, et al. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica 47: 1027-1034, 2017. – reference: 29. Nishizawa T, Suzuki H, Fujimoto A, et al. Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection. J Clin Biochem Nutr 60: 208-210, 2017. – reference: 16. Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Aliment Pharmacol Ther 42: 1315-1326, 2015. – reference: 15. Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 335: 231-238, 2010. – reference: 17. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 20: 153-167, 2005. – reference: 58. Okada M, Nishimura H, Kawashima M, et al. A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome. Aliment Pharmacol Ther 13: 769-774, 1999. – reference: 65. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013 (Epub ahead of print). – reference: 26. Sue S, Shibata W, Sasaki T, et al. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. J Gastroenterol Hepatol 2018 (Epub ahead of print). – reference: 32. Shichijo S, Hirata Y, Niikura R, et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: a multicenter retrospective study in clinical practice. J Dig Dis 17: 670-675, 2016. – reference: 36. Yamada S, Kawakami T, Nakatsugawa Y, et al. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther 7: 550-555, 2016. – reference: 47. Takeda Pharmaceutical Company Limited. Takecab® 10mg/20mg Interview Form [Internet]. [cited 2018 Nov 1]. Available from: https://www.takedamed.com/mcm/medicine/download.jsp?id=162&type=INTERVIEW_FORM (in Japanese) – reference: 9. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372: 392-397, 2008. – reference: 27. Kajihara Y, Shimoyama T, Mizuki I. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. Scand J Gastroenterol 52: 238-241, 2017. – reference: 7. Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 61: 507-513, 2012. – reference: 63. Ueki N, Miyake K, Kusunoki M, et al. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure. Helicobacter 14: 91-99, 2009. – reference: 11. Satake M, Nishikawa J, Fukagawa Y, et al. The long-term efficacy of Helicobacter pylori eradication therapy in patients with idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol 22: 2233-2237, 2007. – reference: 44. Asaka M, Sugiyama T, Kato M, et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6: 254-261, 2001. – reference: 38. Mori N, Nishiura Y, Suga D, et al. Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of Helicobacter pylori. Biomed Rep 9: 169-174, 2018. – reference: 41. Dong SQ, Singh TP, Wei X, Yao H, Wang HL. Review: a Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: is superiority an illusion? Helicobacter 2017 (Epub ahead of print). – reference: 10. Yoon SB, Park JM, Lim CH, Cho YK, Choi MG. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter 19: 243-248, 2014. – reference: 39. Lee SY. Current progress toward eradicating Helicobacter pylori in East Asian countries: differences in the 2013 revised guidelines between China, Japan, and South Korea. World J Gastroenterol 20: 1493-1502, 2014. – reference: 54. Sugimoto M, Ban H, Hira D, et al. Letter: CYP3A4/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan. Aliment Pharmacol Ther 45: 1009-1010, 2017. – reference: 28. Matsumoto H, Shiotani A, Katsumata R, et al. Helicobacter pylori eradication with proton pump inhibitors or potassium-competitive acid blockers: the effect of clarithromycin resistance. Dig Dis Sci 61: 3215-3220, 2016. – reference: 52. Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 12: 317-323, 2007. – reference: 45. Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K, Hasegawa S. Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized, crossover study. Adv Ther 33: 1519-1535, 2016. – reference: 48. Sachs G, Meyer-Rosberg K, Scott DR, Melchers K. Acid, protons and Helicobacter pylori. Yale J Biol Med 69: 301-316, 1996. – reference: 59. Okada M, Oki K, Shirotani T, et al. A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol 33: 640-645, 1998. – reference: 33. Shinozaki S, Nomoto H, Kondo Y, et al. Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori. Kaohsiung J Med Sci 32: 255-260, 2016. – reference: 64. Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer 132: 1272-1276, 2013. – reference: 3. Morris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 82: 192-199, 1987. – reference: 51. Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69: 158-168, 2001. – reference: 8. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 348: g3174, 2014. – reference: 61. Nagahara A, Miwa H, Ogawa K, et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 5: 88-93, 2000. – reference: 19. Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol 6: e94, 2015. – reference: 20. Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 41: 636-648, 2015. – reference: 56. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59: 1143-1153, 2010. – reference: 24. Ozaki H, Harada S, Takeuchi T, et al. Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: a large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy. Digestion 97: 212-218, 2018. – reference: 12. Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 15: 1-20, 2010. – reference: 50. Sachs G, Scott DR, Wen Y. Gastric infection by Helicobacter pylori. Curr Gastroenterol Rep 13: 540-546, 2011. – reference: 6. Ford AC, Gurusamy KS, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev 4: CD003840, 2016. – reference: 23. Maruyama M, Tanaka N, Kubota D, et al. Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial. Can J Gastroenterol Hepatol 2017: 4385161, 2017. – reference: 25. Sue S, Ogushi M, Arima I, et al. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: a multicenter, prospective, randomized trial. Helicobacter 23: e12456, 2018. – reference: 37. Tanabe H, Yoshino K, Ando K, et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Clin Microbiol Antimicrob 17: 29, 2018. – reference: 22. Sue S, Kuwashima H, Iwata Y, et al. The superiority of vonoprazan-based first-line triple therapy with clarithromycin: a prospective multi-center cohort study on Helicobacter pylori eradication. Intern Med 56: 1277-1285, 2017. – reference: 42. Li M, Oshima T, Horikawa T, et al. Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter 23: e12495, 2018. – reference: 57. Yanai A, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: a randomized study in Japan. World J Gastrointest Pharmacol Ther 3: 1-6, 2012. – reference: 62. Nagahara A, Miwa H, Yamada T, Kurosawa A, Ohkura R, Sato N. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 15: 417-421, 2001. – reference: 5. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 12 (Suppl 2): 32-38, 2007. – reference: 2. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust 142: 436-439, 1985. – reference: 4. Asaka M, Kato M, Kudo M, et al. Atrophic changes of gastric mucosa are caused by Helicobacter pylori infection rather than aging: studies in asymptomatic Japanese adults. Helicobacter 1: 52-56, 1996. – reference: 14. Smith SM, O'Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol 20: 9912-9921, 2014. – reference: 31. Sakurai K, Suda H, Ido Y, et al. Comparative study: vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol 23: 668-675, 2017. – reference: 30. Noda H, Noguchi S, Yoshimine T, et al. A novel potassium-competitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori. J Gastrointestin Liver Dis 25: 283-288, 2016. – reference: 49. Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut 43 (Suppl 1): S56-S60, 1998. – reference: 1. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1: 1273-1275, 1983. – reference: 21. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 65: 1439-1446, 2016. – reference: 18. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 23: 460-471, 2003. – reference: 34. Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day ppi-based low-dose clarithromycin triple therapy. Am J Gastroenterol 111: 949-956, 2016. – reference: 55. Okamura T, Suga T, Nagaya T, et al. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. Helicobacter 19: 214-220, 2014. – reference: 46. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 39: 5-12, 1997. – reference: 60. Koizumi W, Tanabe S, Nakatani K, et al. Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study). J Clin Pharm Ther 35: 303-307, 2010. – reference: 13. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 66: 6-30, 2017. – reference: 40. Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther 46: 106-114, 2017. – reference: 35. Tsujimae M, Yamashita H, Hashimura H, et al. A comparative study of a new class of gastric acid suppressant agent named vonoparazan versus esomeprazole for the eradication of Helicobacter pylori. Digestion 94: 240-246, 2016. – reference: 43. Sue S, Ogushi M, Arima I, et al. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: a multicenter, prospective, randomized trial. Helicobacter 23: e12456, 2018. – ident: 39 – ident: 60 doi: 10.1046/j.1523-5378.2000.00013.x – ident: 18 doi: 10.1592/phco.23.4.460.32128 – ident: 33 doi: 10.1038/ajg.2016.182 – ident: 5 doi: 10.1111/j.1523-5378.2007.00563.x – ident: 31 – ident: 15 doi: 10.1124/jpet.110.170274 – ident: 6 doi: 10.1002/14651858.CD003840.pub5 – ident: 55 doi: 10.1136/gut.2009.192757 – ident: 29 doi: 10.15403/jgld.2014.1121.253.7hp – volume: 372 start-page: 392 issn: 0140-6736 year: 2008 ident: 9 publication-title: The Lancet doi: 10.1016/S0140-6736(08)61159-9 – ident: 45 – ident: 54 doi: 10.1111/hel.12124 – ident: 22 – ident: 2 doi: 10.5694/j.1326-5377.1985.tb113443.x – ident: 40 doi: 10.1111/hel.12438 – ident: 43 doi: 10.1046/j.1523-5378.2001.00037.x – volume: 15 start-page: 1 issn: 1083-4389 year: 2010 ident: 12 publication-title: Helicobacter doi: 10.1111/j.1523-5378.2009.00738.x – ident: 38 – ident: 13 doi: 10.1136/gutjnl-2016-312288 – ident: 49 doi: 10.1007/s11894-011-0226-4 – ident: 30 – ident: 19 doi: 10.1038/ctg.2015.18 – ident: 10 doi: 10.1111/hel.12146 – ident: 41 doi: 10.1111/hel.12495 – ident: 8 – ident: 27 – ident: 44 – ident: 51 doi: 10.1111/j.1523-5378.2007.00508.x – ident: 52 doi: 10.1080/00498254.2016.1203505 – ident: 23 – ident: 4 doi: 10.1111/j.1523-5378.1996.tb00008.x – volume: 1 start-page: 1273 issn: 0140-6736 year: 1983 ident: 1 publication-title: The Lancet – ident: 37 doi: 10.3892/br.2018.1111 – ident: 36 doi: 10.1186/s12941-018-0281-x – ident: 14 doi: 10.3748/wjg.v20.i29.9912 – ident: 62 doi: 10.1111/j.1523-5378.2009.00664.x – ident: 63 doi: 10.1002/ijc.27965 – ident: 61 doi: 10.1046/j.1365-2036.2001.00929.x – ident: 53 – ident: 57 – ident: 11 doi: 10.1111/j.1440-1746.2007.04845.x – ident: 24 – ident: 59 doi: 10.1111/j.1365-2710.2009.01092.x – ident: 28 doi: 10.3164/jcbn.16-86 – volume: 43 start-page: S56 issn: 0017-5749 year: 1998 ident: 48 publication-title: Gut doi: 10.1136/gut.43.2008.S56 – ident: 32 doi: 10.1016/j.kjms.2016.04.009 – ident: 47 – ident: 25 doi: 10.1111/jgh.14456 – ident: 20 – ident: 3 – ident: 21 doi: 10.1136/gutjnl-2015-311304 – ident: 58 doi: 10.1007/s005350050150 – ident: 64 doi: 10.1002/14651858.CD008337.pub2 – ident: 42 doi: 10.1111/hel.12456 – ident: 26 doi: 10.1080/00365521.2016.1250157 – ident: 34 doi: 10.1159/000454762 – ident: 56 – ident: 35 doi: 10.4292/wjgpt.v7.i4.550 – ident: 16 doi: 10.1111/apt.13414 – ident: 46 – volume: 61 start-page: 507 issn: 0017-5749 year: 2012 ident: 7 publication-title: Gut doi: 10.1136/gutjnl-2011-300495 – ident: 50 doi: 10.1067/mcp.2001.113959 – ident: 17 doi: 10.2133/dmpk.20.153 |
| SSID | ssj0038792 |
| Score | 2.494696 |
| SecondaryResourceType | review_article |
| Snippet | Helicobacter pylori can infect the gastric mucosa and cause chronic inflammation, resulting in various diseases, including gastric cancer. Eradication of H.... Helicobacter pylori can infect the gastric mucosa and cause chronic inflammation, resulting in various diseases, including gastric cancer. Eradication of H.... |
| SourceID | pubmedcentral proquest pubmed crossref jstage |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 153 |
| SubjectTerms | Amoxicillin Antibiotic resistance Clarithromycin Eradication Gastric cancer Gastric mucosa Helicobacter pylori Internal medicine potassium-competitive acid blocker (P-CAB) proton pump inhibitor (PPI) Proton pump inhibitors Review vonoprazan |
| Title | Efficacy of Vonoprazan for Helicobacter pylori Eradication |
| URI | https://www.jstage.jst.go.jp/article/internalmedicine/59/2/59_2521-18/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/31243237 https://www.proquest.com/docview/2349871922 https://www.proquest.com/docview/2248375194 https://pubmed.ncbi.nlm.nih.gov/PMC7008041 |
| Volume | 59 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Internal Medicine, 2020/01/15, Vol.59(2), pp.153-161 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RQIgL4tFCykOp1GugsR0nRkIIoQXaajl1EbfIdhxYtEq220Uq_Hpm8hIvIUQOucSTROMZf9_4MQPw3YXMIMqaQOQqCoTmLjC5tAHjznLFM0QZmofsn8uzgfh1GV3OQHtcsVHgv1dDO6onNZiMdv__vTtEhz-gbcyhVHvDeu5s1K5G7zLEpCBMPsEc4pMkW--Lbm2BJ3FVKhmBks4fhEm9v-fNNy3CAkcg5IzKpT_Cr_kbpHBX7jV2-nyT5SPUOlmGpYZu-ke1fazAjCtWYaHffHgN9nuUQkLbO7_M_YuyKMcTfa8LH6msj4iEZmKqdM7-mAL7od-b6KyZ5fsMg5Pen-OzoCmnEFiMUaYB59aht4bOaKcdLZAlFq_IMnRalbhcG0quH2MAxmTOcNxDOibzWCpljVQZ_wKzRVm4DfCRkmuLXCLPuUBGkyXCJBFzNpLcZkpoD-JWSaltco1TyYtRijEHaTp9rumUNJ2GiQdhJzmu8228Q-a07odOovG6lxKRSll1qyW7hnTEDccJD7bajkxbU0wZFwrDSsWYB9-6x-iFtLSiC1feYhtGmfmRDQsP1ut-736mtRxUyhOL6BpQhu-nT4rhdZXpOyZCL8KvH5bchEVGEwQ_0IqjLZidTm7dNrKoqdnB-OHn753KNR4Ar_wjfQ |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+Vonoprazan+for+Helicobacter+pylori+Eradication&rft.jtitle=Internal+medicine+%28Tokyo%2C+1992%29&rft.au=Kiyotoki%2C+Shu&rft.au=Nishikawa%2C+Jun&rft.au=Sakaida%2C+Isao&rft.date=2020-01-15&rft.pub=The+Japanese+Society+of+Internal+Medicine&rft.issn=0918-2918&rft.eissn=1349-7235&rft.volume=59&rft.issue=2&rft.spage=153&rft.epage=161&rft_id=info:doi/10.2169%2Finternalmedicine.2521-18&rft_id=info%3Apmid%2F31243237&rft.externalDocID=PMC7008041 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-2918&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-2918&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-2918&client=summon |